Chronic hepatitis type C
Conditions
Interventions
Patients were treated by simeprevir plus peginterferon/ribavirin therapy with BCAA enriched supplement.
Patients were treated by simeprevir plus peginterferon/ribavirin therapy without BCAA enriched s
Sponsors
Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients who infected HCV-serotype1 2) age, over 20 years old and under 75 years old 3) male and female 4) patients who don't diagnosed cirrhosis by imaging or blood examination 5) patients who has no HCC by imaging examination
Exclusion criteria
Exclusion criteria: 1) Patient whose serum HCV RNA level under 5.0 log IU/ml and who taken initial therapy. 2) Patients with sensitivities for peg-interferon alpha 2b or other interferons. 3) Patients with sensitivities for vaccine. 4) Patients with sensitivities for ribavirin or other nucleic acid analogs. 5) a pregnant woman, or woman who may pregnant and who are nursing. 6) PAtients who had bad controled heart disease. 7) Patients who had hemoglobinemia. 8) Patients who had Chronic renal failure or whose creatinine clearance under 50ml/min. 9) Patients who had depression. 10) Patients who had severe liver disfunction or bile duct obstruction. 11) Patients who had cerebral hemorrhage or cerebral infarction. 12) PAtients who medicated by shousaikoto. 13) Patients who had autoimmune hepatitis. 14) Patients who had chronic hepatitis type B, alcoholic liver injury. 15) Patients who were disqualified by doctor in attendance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained virological response | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Negative conversion rate of HCV-RNA (at 4W, 12W, 24W of therapy) 2) Change in hemoglobin 3) Dose of drug (simeprevir, peginterferon, ribavirin) 4) Improvement of insulin resistance 5) Improvement of loss of zinc 6) Improvement of BTR 7) Occurrence of side effect | — |
Countries
Japan
Contacts
Public ContactIsao Hidaka
Yamaguchi Univercity Graduate School of Medicine Department of Gastroenterology and Hepatology
Outcome results
None listed